Items Tagged ‘CHRONOS-1 clinical study’

May 23, 2018

FDA Approves Aliqopa for Relapsed Follicular Lymphoma


The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), a novel precision cancer medicine that inhibits phosphatidylinositol 3-kinase (PI3K), for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.   Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin’s lymphoma (NHL), […]

View full entry

Tags: Aliqopa, CHRONOS-1 clinical study, copanlisib, follicular non-hodgkin lymphoma, News, Non-Hodgkin's Lymphoma, Precision Cancer Medicine